Vitiligo: an update on current pharmacotherapy and future directions

Bibliography

• Spritz RA. Recent progress in the genetics of generalized vitiligo. J Genet Genomics 2011;38:271-8
   PubMedGoogle Scholar
• Schallreuter KU, Bahadoran P, Picardo M, Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol 2008;17:139-40
   PubMed Web of Science ®Google Scholar
• Sandoval-Cruz M, García-Carrasco M, Sánchez-Porras R, Immunopathogenesis of vitiligo. Autoimmun Rev 2011;10:762-5
   PubMed Web of Science ®Google Scholar
• Eskandani M, Golchai J, Pirooznia N, Oxidative stress level and tyrosinase activity in vitiligo patients. Indian J Dermatol 2010;55:15-19
   PubMedGoogle Scholar
• Al Abadie MSK, Senior HI, Bleehen SS, Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol 1994;131:160-5
   PubMedGoogle Scholar
• Moretti S, Spallanzani A, Amato L, New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 2002;15:87-92
   PubMedGoogle Scholar
• Moretti S, Spallanzani A, Amato L, Vitiligo and epidermal microenvironment: possible involvement of keratinocyte-derived cytokines. Arch Dermatol 2002;138:273-4
   PubMedGoogle Scholar
• Birol A, Kisa U, Kurtipek GS, Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo. Int J Dermatol 2006;45:992-3
   PubMed Web of Science ®Google Scholar
• Gauthier Y, Cario Andre M, Taïeb A. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res 2003;16:322-32
   PubMedGoogle Scholar
• Taïeb A. Vitiligo as an inflammatory skin disorder: a therapeutic perspective. Pigment Cell Melanoma Res 2012;25:9-13
   PubMedGoogle Scholar
• Ezzedine K, Lim HW. Suzuki T, et al.; on behalf of the Vitiligo Global Issue Consensus Conference panelists. Revised classification/nomenclature of vitiligo and related issues: the vitiligo global issues consensus conference. Pigment Cell Melanoma Res 2012;25:E1-E13
   Web of Science ®Google Scholar
• Cheng YP, Chiu HY, Jee SH, Tsai TF. Excimer light photototherapy of segmental and non-segmental vitiligo: experience in Taiwan. Photodermatol Photoimmunol Photomed 2012;28:6-11
   PubMed Web of Science ®Google Scholar
• Kathuria S, Khaitan BK, Ramam M, Sharma VK. Segmental vitiligo: a randomized controlled trial to evaluate efficacy and safety of 0.1% tacrolimus ointment vs 0.05% fluticasone propionate cream. Indian J Dermatol Venereol Leprol 2012;78:68-73
   PubMedGoogle Scholar
• Do JE, Shin JY, Kim DY, The effect of 308 nm excimer laser on segmental vitiligo: a retrospective study of 80 patients with segmental vitiligo. Photodermatol Photoimmunol Photomed 2011;27:147-51
   PubMed Web of Science ®Google Scholar
• Lee DY, Kim CR, Park JH, Lee JH. The incidence of leukotrichia in segmental vitiligo: implication of poor response to medical treatment. Int J Dermatol 2011;50:925-7
   PubMedGoogle Scholar
• Ezzedine K, Gauthier Y, Léauté-Labrèze C, Segmental vitiligo associated with generalized vitiligo (mixed vitiligo): a retrospective case series of 19 patients. J Am Acad Dermatol 2011;65:965-71
   PubMedGoogle Scholar
• Taieb A, Picardo M; VETF members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007;20:27-35
   PubMedGoogle Scholar
• Falabella R. Vitiligo and the melanocyte reservoir. Indian J Dermatol 2009;54:313-18
   PubMedGoogle Scholar
• Cui J, Shen LY, Wang GC. Role of hair follicles in the repigmentation of vitiligo. J Invest Dermatol 1991;97:410-16
   PubMed Web of Science ®Google Scholar
• Nishimura EK. Melanocyte stem cells: a melanocyte reservoir in hair follicles for hair and skin pigmentation. Pigment Cell Melanoma Res 2011;24:2401-10
   Google Scholar
• Ortonne JP, Schmitt D, Thivolet J. PUVA-induced repigmentation of vitiligo: scanning electron microscopy of hair follicles. J Invest Dermatol 1980;74:40
   PubMed Web of Science ®Google Scholar
• Nishimura EK, Jordan SA, Oshima H, Dominant role of the niche in melanocyte stem-cell fate determination. Nature 2002;416:854-60
   PubMed Web of Science ®Google Scholar
• Hoerter JD, Bradley P, Casillas A, Extrafollicular dermal melanocyte stem cells and melanoma. Stem Cells Int 2012; Published online 10 May 2012; doi:2012:407079
   PubMedGoogle Scholar
• Felsten LM, Alikhan A, Petronic-Rosic V. Vitiligo: a comprehensive overview part II: treatment options and approach to treatment. J Am Acad Dermatol 2011;65:493-514
   PubMed Web of Science ®Google Scholar
• Bleehen SS. The treatment of vitiligo with topical corticosteroids. Light and electronmicroscopic studies. Br J Dermatol 1976;94:43-50
   PubMed Web of Science ®Google Scholar
• Tadicherla S, Ross K, Shenefelt PD, Fenske NA. Topical corticosteroids in dermatology. J Drugs Dermatol 2009;8:1093-105
   PubMed Web of Science ®Google Scholar
• Njoo MD, Spuls PI, Bos JD, Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature. Arch Dermatol 1998;134:1532-40
   PubMed Web of Science ®Google Scholar
• Kwinter J, Pelletier J, Khambalia A, High-potency steroid use in children with vitiligo: a retrospective study. J Am Acad Dermatol 2007;56:236-41
   PubMed Web of Science ®Google Scholar
• Ho N, Pope E, Weinstein M, A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0·1% vs. clobetasol propionate 0·05% in childhood vitiligo. Br J Dermatol 2011;165:626-32
   PubMedGoogle Scholar
• Cockayne SE, Messenger AG, Gawkrodger DJ. Vitiligo treated with topical corticosteroids: children with head and neck involvement respond well. J Am Acad Dermatol 2002;46:964-5
   PubMedGoogle Scholar
• Sassi F, Cazzaniga S, Tessari G, Randomized controlled trial comparing the effectiveness of 308-nm excimer laser alone or in combination with topical hydrocortisone 17-butyrate cream in the treatment of vitiligo of the face and neck. Br J Dermatol 2008;159:1186-91
   PubMed Web of Science ®Google Scholar
• Westerhof W, Nieuweboer-Krobotova L, Mulder PG, Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol 1999;135:1061-6
   PubMedGoogle Scholar
• Bayoumi W, Fontas E, Sillard L, Effect of a preceding laser dermabrasion on the outcome of combined therapy with narrowband ultraviolet B and potent topical steroids for treating nonsegmental vitiligo in resistant localizations. Br J Dermatol 2012;166:208-11
   PubMed Web of Science ®Google Scholar
• Chan S, Gerson B, Subramaniam S. The role of copper, molybdenum, selenium, and zinc in nutrition and health. Clin Lab Med 1998;18:673-85
   PubMed Web of Science ®Google Scholar
• Shibata T, Prota G, Mishima Y. Non-melanosomal regulatory factors in melanogenesis. J Invest Dermatol 1993;100:274S-80S
   Google Scholar
• Yaghoobi R, Omidian M, Bagherani N. Comparison of therapeutic efficacy of topical corticosteroid and oral zinc sulfate-topical corticosteroid combination in the treatment of vitiligo patients: a clinical trial. BMC Dermatol 2011;11:7
   PubMedGoogle Scholar
• Grimes PE, Morris R, Avaniss-Aghajani E, Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004;51:52-61
   PubMed Web of Science ®Google Scholar
• Shi F, Erf GF. IFN-γ, IL-21, and IL-10 co-expression in evolving autoimmune vitiligo lesions of Smyth line chickens. J Invest Dermatol 2012;132:642-9
   PubMed Web of Science ®Google Scholar
• Lan CC, Chen GS, Chiou MH, FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol 2005;153:498-505
   PubMed Web of Science ®Google Scholar
• Lee KY, Jeon SY, Hong JW, Endothelin-1 enhances the proliferation of normal human melanocytes in a paradoxical manner from the TNF-α-inhibited condition, but tacrolimus promotes exclusively the cellular migration without proliferation: a proposed action mechanism for combination therapy of phototherapy and topical tacrolimus in vitiligo treatment. J Eur Acad Dermatol Venereol 2012; Published online 9 Mar 2012; doi: 10.1111/j.1468-3083.2012.04498.x
   Google Scholar
• Udompataikul M, Boonsupthip P, Siriwattanagate R. Effectiveness of 0.1% topical tacrolimus in adult and children patients with vitiligo. J Dermatol 2011;38:536-40
   PubMedGoogle Scholar
• Silverberg JI, Silverberg NB. Topical tacrolimus is more effective for treatment of vitiligo in patients of skin of color. J Drugs Dermatol 2011;10:507-10
   PubMedGoogle Scholar
• Juan D, Qianxi X, Zhou C, Jianzhong Z. Clinical efficacy and safety of tacrolimus ointment in patients with vitiligo. J Dermatol 2011;38:1092-4
   PubMedGoogle Scholar
• Nisticò S, Chiricozzi A, Saraceno R, Vitiligo treatment with monochromatic excimer light and tacrolimus: results of an open randomized controlled study. Photomed Laser Surg 2012;30:26-30
   PubMed Web of Science ®Google Scholar
• Lotti T, Buggiani G, Troiano M, Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. J Dermatol Ther 2008;21:S20-6
   PubMed Web of Science ®Google Scholar
• Stinco G, Piccirillo F, Sallustio M, Patrone P. Facial flush reaction after alcohol ingestion during topical pimecrolimus and tacrolimus treatment. Dermatology 2009;218:71-2
   PubMedGoogle Scholar
• Ring J, Möhrenschlager M, Henkel V. The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf 2008;31:185-98
   PubMed Web of Science ®Google Scholar
• Guideline on Vitiligo. Developed by the guideline subcommittee “Vitiligo” of the European Dermatologic Forum. Available from: http://www.sidemast.org/download/sidemast_20120227103850.pdf [Last Accessed 25 April 2012]
   Google Scholar
• De Francesco V, Stinco G, Laspina S, Immunohistochemical study before and after narrow band (311 nm) UVB treatment in vitiligo. Eur J Dermatol 2008;18:292-6
   PubMedGoogle Scholar
• Wu CS, Lan CC, Wang LF, Effects of psoralen plus ultraviolet A irradiation on cultured epidermal cells in vitro and patients with vitiligo in vivo. Br J Dermatol 2007;156:122-9
   PubMedGoogle Scholar
• Yones SS, Palmer RA, Garibaldinos TM, Hawk JL. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs narrowband-UV-B therapy. Arch Dermatol 2007;143:578-84
   PubMedGoogle Scholar
• Arca E, Tastan HB, Erbil AH, Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo. J Dermatol 2006;33:338-43
   PubMed Web of Science ®Google Scholar
• Kanwar AJ, Dogra S. Narrow-band UVB for the treatment of generalized vitiligo in children. Clin Exp Dermatol 2005;30:332-6
   PubMed Web of Science ®Google Scholar
• Kanwar AJ, Dogra S, Parsad D, Kumar B. Narrow-band UVB for the treatment of vitiligo: an emerging effective and well tolerated therapy. Int J Dermatol 2005;44:57-60
   PubMed Web of Science ®Google Scholar
• Dell'Anna ML, Mastrofrancesco A, Sala R, Antioxidants and narrow band UVB in the treatment of vitiligo: a double blind placebo controlled trial. Clin Exp Dermatol 2007;32:631-6
   PubMed Web of Science ®Google Scholar
• Gamil H, Attwa E, Ghonemy S. Narrowband ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of generalized vitiligo. Clin Exp Dermatol 2010;35:919-21
   PubMedGoogle Scholar
• Bakis-Petsoglou S, Le Guay JL, Wittal R. A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo. Br J Dermatol 2009;161:910-17
   PubMedGoogle Scholar
• Bhatnagar A, Kanwar AJ, Parsad D, De D. Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study. J. Eur Acad Dermatol Venereol 2007;21:638-42
   PubMed Web of Science ®Google Scholar
• Parsad D, Kanwar AJ, Kumar B. Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo. J Eur Acad Dermatol Venereol 2006;20:175-7
   PubMed Web of Science ®Google Scholar
• Archier E, Devaux S, Castela E, Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012;26(S3):22-31
   PubMedGoogle Scholar
• Pacifico A, Leone G. Photo(chemo)therapy for vitiligo. Photodermatol Photoimmunol Photomed 2011;27:261-7
   PubMed Web of Science ®Google Scholar
• Kao CH, Yu HS. Depletion and repopulation of Langerhans cells in non segmental type vitiligo. J Dermatol 1990;17:287-96
   PubMedGoogle Scholar
• Kao CH, Yu HS. Effects of PUVA on melanocytes in vitiligo and in patients with vitiligo vulgaris. J Invest Dermatol 1992;98:734-40
   PubMedGoogle Scholar
• Lei TC, Virador V, Yasumoto K, Stimulation of melanoblast pigmentation by 8-methoxypsoralen: the involvement of microphthalmia-associated transcription factor, the protein kinase A signal pathway, and proteasome-mediated degradation. J Invest Dermatol 2002;119:1341-9
   PubMed Web of Science ®Google Scholar
• Abdel-Naser MB, Hann SK, Bystryn JC. Oral psoralen with UV-A therapy releases circulating growth factor(s) that stimulates cell proliferation. Arch Dermatol 1997;133:1530-3
   PubMedGoogle Scholar
• Mai DW, Omohundro C, Dijkstra JW, Childhood vitiligo successfully treated with bath PUVA. Pediatr Dermatol 1998;15:53-5
   PubMed Web of Science ®Google Scholar
• Wlaschek M, Ma W, Jansen-Dürr P, Scharffetter-Kochanek K. Photoaging as a consequence of natural and therapeutic ultraviolet irradiation- studies on PUVA-induced senescence-like growth arrest of human dermal fibroblasts. Exp Gerontol 2003;38:1265-70
   PubMedGoogle Scholar
• Briganti S, Wlaschek M, Hinrichs C, Small molecular antioxidants effectively protect from PUVA-induced oxidative stress responses underlying fibroblast senescence and photoaging. Free Radic Biol Med 2008;45:636-44
   PubMedGoogle Scholar
• Stern RS. PUVA follow up study. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001;44:755-61
   PubMed Web of Science ®Google Scholar
• Lindelo¨f B, Sigurgeirsson B, Tegner E, PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999;141:108-12
   PubMed Web of Science ®Google Scholar
• Lunder EJ, Stern RS. Merkel-cell carcinomas in patients treated with methoxsalen and ultraviolet A radiation. N Engl J Med 1998;339:1247-8
   PubMedGoogle Scholar
• Halder RM, Battle EF, Smith EM. Cutaneous malignancies in patients treated with psoralen photochemotherapy (PUVA) for vitiligo. Arch Dermatol 1995;131:734-5
   PubMedGoogle Scholar
• Buckley DA, Rogers S. Multiple keratoses and squamous carcinoma after PUVA treatment of vitiligo. Clin Exp Dermatol 1996;21:43-5
   PubMedGoogle Scholar
• Takeda H, Mitsuhashi Y, Kondo S. Multiple squamous cell carcinomas in situ in vitiligo lesions after long-term PUVA therapy. J Am Acad Dermatol 1998;38:268-70
   PubMedGoogle Scholar
• Park HS, Lee YS, Chun DK. Squamous cell carcinoma in vitiligo lesion after long-term PUVA therapy. J Eur Acad Dermatol Venereol 2003;17:578-80
   PubMedGoogle Scholar
• Birlea SA, Costin GE, Norris DA. Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets 2008;9:345-59
   PubMedGoogle Scholar
• Chiavérini C, Passeron T, Ortonne JP. Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol Venereol 2002;16:137-8
   PubMed Web of Science ®Google Scholar
• Gargoom AM, Duweb GA, Elzorghany AH, Calcipotriol in the treatment of childhood vitiligo. Int J Clin Pharmacol Res 2004;24:11-14
   PubMedGoogle Scholar
• Travis LB, Silverberg NB. Calcipotriene and corticosteroid combination therapy for vitiligo. Pediatr Dermatol 2004;21:495-8
   PubMed Web of Science ®Google Scholar
• Ameen M, Exarchou V, Chu AC. Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo. Br J Dermatol 2001;145:476-9
   PubMedGoogle Scholar
• Goldinger SM, Dummer R, Schmid P, Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. J Eur Acad Dermatol Venereol 2007;21:504-8
   PubMedGoogle Scholar
• Parsad D, Kanwar AJ. Topical vitamin D3 analogues in the treatment of vitiligo. Pigment Cell Melanoma Res 2009;22:487-8
   PubMedGoogle Scholar
• Parsad D, Pandhi R, Dogra S, Kumar B. Clinical study of repigmentation patterns with different treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiliginous patches. J Am Acad Dermatol 2004;50:63-7
   PubMed Web of Science ®Google Scholar
• Park K.K, Liao W, Murase JE. A Review of Monochromatic Excimer Light (MEL) in Vitiligo. Br J Dermatol 2012; Published online 23 Apr 2012; doi: 10.1111/j.1365-2133.2012.11008.x
   Google Scholar
• Lotti T, Berti S, Moretti S. Vitiligo therapy. Expert Opin Pharmacother 2009;10:2779-85
   PubMed Web of Science ®Google Scholar
• Spencer JM, Nossa R, Ajmeri J. Treatment of vitiligo with the 308-nm excimer laser: a pilot study. J Am Acad Dermatol 2002;46:727-31
   PubMed Web of Science ®Google Scholar
• Leone G, Iacovelli P, Paro Vidolin A, Picardo M. Monochromatic excimer light 308 nm in the treatment of vitiligo: a pilot study. J Eur Acad Dermatol Venereol 2003;17:531-7
   PubMed Web of Science ®Google Scholar
• Hofer A, Hassan AS, Legat FJ, The efficacy of excimer laser (308 nm) for vitiligo at different body sites. J Eur Acad Dermatol Venereol 2006;20:558-64
   PubMed Web of Science ®Google Scholar
• Chimento SM, Newland M, Ricotti C, A pilot study to determine the safety and the efficacy of monochromatic excimer light in the treatment of vitiligo. J Drugs Dermatol 2008;7:258-63
   PubMed Web of Science ®Google Scholar
• Casacci M, Thomas P, Pacifico A, Comparison between 308-nm monochromatic excimer light and narrowband UVB phototherapy (311-313 nm) in the treatment of vitiligo–a multicentre controlled study. J Eur Acad Dermatol Venereol 2007;21:956-63
   PubMed Web of Science ®Google Scholar
• Oh SH, Kim T, Jee H, Combination treatment of non-segmental vitiligo with a 308-nm xenon chloride excimer laser and topical high-concentration tacalcitol: a prospective, single-blinded, paired, comparative study. J Am Acad Dermatol 2011;65:428-30
   PubMedGoogle Scholar
• Passeron T, Ostovari N, Zakaria W, Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004;140:1065-9
   PubMed Web of Science ®Google Scholar
• Menchini G, Tsoureli-Nikita E, Hercogova J. Narrowband UV-B microphototherapy: a new treatment of vitiligo. J Eur Acad Dermatol Venereol 2003;17:171-7
   PubMed Web of Science ®Google Scholar
• Kim SM, Lee HS, Hann SK. The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patients. Int J Dermatol 1999;38:546-50
   PubMed Web of Science ®Google Scholar
• Radakovic-Fijan S, Fürnsinn-Friedl AM, Hönigsmann H, Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol 2001;44:814-17
   PubMed Web of Science ®Google Scholar
• Pasricha JS, Khaitan BK. Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease. Int J Dermatol 1993;32:753-7
   PubMed Web of Science ®Google Scholar
• Patel NS, Paghdal KV, Cohen GF. Advanced treatment modalities for vitiligo. 2012;38:381-91
   Google Scholar
• Pianigiani E, Andreassi A, Andreassi L. Autografts and cultured epidermis in the treatment of vitiligo. Clin Dermatol 2005;23:424-9
   PubMed Web of Science ®Google Scholar
• Chen YF, Yang PY, Hu DN, Treatment of vitiligo by transplantation of cultured pure melanocyte suspension: analysis of 120 cases. J Am Acad Dermatol 2004;51:68-74
   PubMed Web of Science ®Google Scholar
• Njoo MD, Westerhof W, Bos JD, Bossuvt PM. A systematic review of autologous transplantation methods in vitiligo. Arch Dermatol 1998;134:1543-9
   PubMed Web of Science ®Google Scholar
• Fongers A, Wolkerstorfer A, Nieuweboer-Krobotova L, Long-term results of 2-mm punch grafting in patients with vitiligo vulgaris and segmental vitiligo: effect of disease activity. Br J Dermatol 2009;161:1105-11
   PubMed Web of Science ®Google Scholar
• El-Zawahry BM, Zaki NS, Bassiouny DA, Autologous melanocyte-keratinocyte suspension in the treatment of vitiligo. J Eur Acad Dermatol Venereol 2011;25:215-20
   PubMedGoogle Scholar
• Pandya V, Parmar KS, Shah BJ, Bilimoria FE. A study of autologous melanocyte transfer in treatment of stable vitiligo. Indian J Dermatol Venereol Leprol 2005;71:393-7
   PubMedGoogle Scholar
• Pianigiani E, Risulo M, Andreassi A, Autologous epidermal cultures and narrow-band ultraviolet B in the surgical treatment of vitiligo. Dermatol Surg 2005;31:155-9
   PubMed Web of Science ®Google Scholar
• Chen YF, Yang PY, Hu DN, Treatment of vitiligo by transplantation of cultured pure melanocyte suspension: analysis of 120 cases. J Am Acad Dermatol 2004;51:68-74
   PubMed Web of Science ®Google Scholar
• Schallreuter KU, Wood JM, Berger J. Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol 1991;97:1081-5
   PubMed Web of Science ®Google Scholar
• Schallreuter KU, Wood JM, Lemke KR, Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology 1995;190:223-9
   PubMed Web of Science ®Google Scholar
• Schallreuter KU, Moore J, Behrens-Williams S, Rapid initiation of repigmentation in vitiligo with Dead Sea climatotherapy in combination with pseudocatalase (PC-KUS). Int J Dermatol 2002;41:482-7
   PubMed Web of Science ®Google Scholar
• Schallreuter KU, Krüger C, Würfel BA, From basic research to the bedside: efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo. Int J Dermatol 2008;47:743-53
   PubMedGoogle Scholar
• Sakai Y, Fujita K, Sakai H, Mizuno K. Prostaglandin E2 regulates the expression of basic fibroblast growth factor messenger RNA in normal human fibroblasts. Kobe J Med Sci 2001;47:35-45
   PubMedGoogle Scholar
• Puri N, van der Weel MB, de Wit FS, Basic fibroblast growth factor promotes melanin synthesis by melanocytes. Arch Dermatol Res 1996;288:633-5
   PubMed Web of Science ®Google Scholar
• Parsad D, Pandhi R, Dogra S, Topical prostaglandin analog (PGE2) in vitiligo–a preliminary study. Int J Dermatol 2002;41:942-5
   PubMed Web of Science ®Google Scholar
• Kapoor R, Phiske MM, Jerajani HR. Evaluation of safety and efficacy of topical prostaglandin E2 in treatment of vitiligo. Br J Dermatol 2009;160:861-3
   PubMed Web of Science ®Google Scholar
• Schallreuter KU, Chavan B, Rokos H, Levenig C. Decreased phenylalanine uptake and turnover in patients with vitiligo. Mol Genet Metab 2005;86:S27-33
   Web of Science ®Google Scholar
• Wolff K, Goldsmith LA, Katz SI, Fitzpatrick's dermatology in general medicine. 7th edition. McGraw-Hill; New York: 2008
   Google Scholar
• Camacho F, Mazuecos J. Treatment of vitiligo with oral and topical phenylalanine: 6 years of experience. Arch Dermatol 1999;135:216-17
   PubMedGoogle Scholar
• Greiner D, Ochsendorf FR, Milbradt R. Vitiligo therapy with phenylalanine/UVA. Catamnestic studies after five years. Hautarzt 1994;45:460-3
   PubMedGoogle Scholar
• van den Boorn JG, Melief CJ, Luiten RM. Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity. Pigment Cell Melanoma Res 2011;24:673-9
   PubMed Web of Science ®Google Scholar
• AlGhamdi KM, Kumar A. Depigmentation therapies for normal skin in vitiligo universalis. J Eur Acad Dermatol Venereol 2011;25:749-57
   PubMedGoogle Scholar
• Bolognia JL, Lapia BK, Somma S. Depigmentation therapy. Dermatol Ther 2001;14:29-34
   Google Scholar
• Rao J, Fitzpatrick RE. Use of the Q-switched 755-nm alexandrite laser to treat recalcitrant pigment after depigmentation therapy for vitiligo. Dermatol Surg 2004;30:1043-5
   PubMedGoogle Scholar
• Kasraee B, Fallahi MR, Ardekani GS, Retinoic acid synergistically enhances the melanocytotoxic and depigmenting effects of monobenzylether of hydroquinone in black guinea pig skin. Exp Dermatol 2006;15:509-14
   PubMedGoogle Scholar
• Gupta D, Kumari R, Thappa DM. Depigmentation therapies in vitiligo. Indian J Dermatol Venereol Leprol 2012;78:49-58
   PubMedGoogle Scholar
• Njoo MD, Vodegel RM, Westerhof W. Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q-switched ruby laser. J Am Acad Dermatol 2000;42:760-9
   PubMed Web of Science ®Google Scholar
• Di Nuzzo S, Masotti A. Depigmentation therapy in vitiligo universalis with cryotherapy and 4-hydroxyanisole. Clin Exp Dermatol 2010;35:215-16
   PubMedGoogle Scholar
• Carlie G, Ntusi NB, Hulley PA, Kidson SH. KUVA (khellin plus ultraviolet A) stimulates proliferation and melanogenesis in normal human melanocytes and melanoma cells in vitro. Br J Dermatol 2003;149:707-17
   PubMedGoogle Scholar
• Hofer A, Kerl H, Wolf P, Long-term results in the treatment of vitiligo with oral khellin plus UVA. Eur J Dermatol 2001;11:225-9
   PubMed Web of Science ®Google Scholar
• Valkova S, Trashlieva M, Christova P. Treatment of vitiligo with local khellin and UVA: comparison with systemic PUVA. Clin Exp Dermatol 2004;29:180-4
   PubMed Web of Science ®Google Scholar
• de Leeuw J, Assen YJ, van der Beek N, Treatment of vitiligo with khellin liposomes, ultraviolet light and blister roof transplantation. J Eur Acad Dermatol Venereol 2011;25:74-81
   PubMed Web of Science ®Google Scholar
• Saraceno R, Nisticò SP, Capriotti E, Chimenti S. Monochromatic excimer light 308 nm in monotherapy and combined with topical khellin 4% in the treatment of vitiligo: a controlled study. Dermatol Ther 2009;22:391-4
   PubMedGoogle Scholar
• Jain A, Mal J, Mehndiratta V, Study of oxidative stress in vitiligo. Indian J Clin Biochem 2011;26:78-81
   PubMedGoogle Scholar
• Kostyuk VA, Potapovich AI, Cesareo E, Dysfunction of glutathione S-transferase leads to excess 4-hydroxy-2-nonenal and H(2)O(2) and impaired cytokine pattern in cultured keratinocytes and blood of vitiligo patients. Antioxid Redox Signal 2010;13:607-20
   PubMed Web of Science ®Google Scholar
• Dell'Anna ML, Ottaviani M, Bellei B, Membrane lipid defects are responsible for the generation of reactive oxygen species in peripheral blood mononuclear cells from vitiligo patients. J Cell Physiol 2010;223:187-93
   PubMed Web of Science ®Google Scholar
• Bhattacharya SK, Dutta AK, Mandal SB, Chatterjee A. Ascorbic acid in vitiligo. Indian J Dermatol 1981;26:4-11
   PubMedGoogle Scholar
• Akyol M, Celik VK, Ozcelik S, The effects of vitamin E on the skin lipid peroxidation and the clinical improvement in vitiligo patients treated with PUVA. Eur J Dermatol 2002;12:24-6
   PubMedGoogle Scholar
• Schallreuter KU, Rokos H. Vitix–a new treatment for vitiligo? Int J Dermatol 2005;44:969-70
   PubMedGoogle Scholar
• Gonzalez S, Pathak MA, Cuevas J, Topical or oral administration with an extract of polypodium leucotomos prevents acute sunburn and psoralen-induced phototoxic reactions as well as depletion of Langerhans cells in human skin. Photodermatol Photoimmunol Photomed 1997;13:50-60
   PubMed Web of Science ®Google Scholar
• Middelkamp-Hup MA, Bos JD, Rius-Diaz F, Treatment of vitiligo vulgaris with narrowband UVB and oral polypodium leucotomos extract: a randomized double-blind placebo-controlled study. J Eur Acad Dermatol Venereol 2007;21:942-50
   PubMed Web of Science ®Google Scholar
• Szczurko O, Shear N, Taddio A, Boon H. Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial. BMC Complement Altern Med 2011;11:21
   PubMedGoogle Scholar
• Garcia F, Pivel JP, Guerrero A, Phenolic components and antioxidant activity of fernblock, an aqueous extract of the aerial parts of the fern polypodium leucotomos. Methods Find Exp Clin Pharmacol 2006;28:157-60
   PubMedGoogle Scholar
• Jańczyk A, Garcia-Lopez MA, Fernandez-Peñas P, A Polypodium leucotomos extract inhibits solar-simulated radiation-induced TNF-alpha and iNOS expression, transcriptional activation and apoptosis. Exp Dermatol 2007;16:823-9
   PubMedGoogle Scholar
• Zattra E, Coleman C, Arad S, Polypodium leucotomos extract decreases UV-induced Cox-2 expression and inflammation, enhances DNA repair, and decreases mutagenesis in hairless mice. Am J Pathol 2009;175:1952-61
   PubMedGoogle Scholar
• Dell'Anna ML, Mastrofrancesco A, Sala R, Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial. Clin Exp Dermatol 2007;32:631-6
   PubMed Web of Science ®Google Scholar
• Jayanth DP, Pai BS, Shenoi SD, Balachandran C. Efficacy of antioxidants as an adjunct to photochemotherapy in vitiligo: a case study of 30 patients. Indian J Dermatol Venereol Leprol 2002;68:202-5
   PubMedGoogle Scholar
• van Geel NA, Mollet IG, De Schepper S, First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res 2010;23:375-84
   PubMed Web of Science ®Google Scholar
• Anbar T-D, Abdel-Raouf H, Awad SS, Ragaie MH. Perifollicular inflammatory infiltrate in vitiligo. Int J Dermatol 2011;50:234-7
   PubMedGoogle Scholar
• Anbar TS, Abdel-Raouf H, Awad SS, Presence of eosinophils in the inflammatory infiltrate of nonsegmental vitiligo: a retrospective study. Clin Exp Dermatol 2009;34:e496-7
   Google Scholar
• Wang CQ, Cruz-Inigo AE, Fuentes-Duculan J, Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS One 2011;6:e18907
   PubMed Web of Science ®Google Scholar
• Bassiouny DA, Shaker O. Role of interleukin-17 in the pathogenesis of vitiligo. Clin Exp Dermatol 2011;36:292-7
   PubMed Web of Science ®Google Scholar
• Ben Ahmed M, Zaraa I, Rekik R, Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo. Pigment Cell Melanoma Res 2012;25:99-109
   PubMed Web of Science ®Google Scholar
• Gupta AK, Ellis CN, Nickoloff BJ, Oral cyclosporine in the treatment of inflammatory and non inflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 1990;126:339-50
   PubMedGoogle Scholar
• Gokhale BB. Cyclophosphamide and vitiligo. Int J Dermatol 1979;18:92
   PubMedGoogle Scholar
• Radmanesh M, Saedi K. The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatolog Treat 2006;17:151-3
   PubMed Web of Science ®Google Scholar
• Sandra A, Pai S, Shenoi SD. Unstable vitiligo responding to methotrexate. Indian J Dermatol Venereol Leprol 1998;64:309
   PubMedGoogle Scholar
• Simón JA, Burgos-Vargas R. Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab. Dermatology 2008;216:234-5
   PubMed Web of Science ®Google Scholar
• Alghamdi KM, Khurrum H, Rikabi A. Worsening of vitiligo and onset of new psoriasiform dermatitis following treatment with infliximab. J Cutan Med Surg 2011;15:280-4
   PubMed Web of Science ®Google Scholar
• Ramírez-Hernández M, Marras C, Martínez-Escribano JA. Infliximab-induced vitiligo. Dermatology 2005;210:79-80
   PubMed Web of Science ®Google Scholar
• Smith DI, Heffernan MP. Vitiligo after the resolution of psoriatic plaques during treatment with adalimumab. J Am Acad Dermatol 2008;58:S50-2
   PubMed Web of Science ®Google Scholar
• Posada C, Flórez A, Batalla A, Vitiligo during treatment of Crohn's disease with adalimumab: adverse effect or co-occurrence? Case Rep Dermatol 2011;3:28-31
   PubMedGoogle Scholar
• Rigopoulos D, Gregoriou S, Larios G, Etanercept in the treatment of vitiligo. Dermatology 2007;215:84-5
   PubMed Web of Science ®Google Scholar
• Campanati A, Giuliodori K, Ganzetti G, A patient with psoriasis and vitiligo treated with etanercept. Am J Clin Dermatol 2010;11:S46-8
   PubMed Web of Science ®Google Scholar
• Alghamdi KM, Khurrum H, Taieb A, Ezzedine K. Treatment of generalized vitiligo with anti-TNF-α agents. J Drugs Dermatol 2012;11:534-9
   PubMed Web of Science ®Google Scholar
• Parsad D, Kanwar A. Oral minocycline in the treatment of vitiligo- a preliminary study. Dermatol Ther 2010;23:305-7
   PubMed Web of Science ®Google Scholar
• Song X, Xu A, Pan W, Minocycline protects melanocytes against H2O2-induced cell death via JNK and p38 MAPK pathways. Int J Mol Med 2008;22:9-16
   PubMed Web of Science ®Google Scholar
• Barnetson RS, Ooi TK. Zhuang L, et al. [Nle4-D-Phe7]-alphamelanocyte- stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol 2006;126:1869-78
   PubMed Web of Science ®Google Scholar
• Harms J, Lautenschlager S, Minder CE, Minder EI. An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria. N Engl J Med 2009;360:306-7
   PubMed Web of Science ®Google Scholar